Biohaven Ltd. BHVN
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Biohaven Ltd. is a clinical-stage biopharmaceutical company that focuses on creating novel therapies for neurological and neuropsychiatric diseases. Its primary function is to develop innovative drugs that address unmet medical needs, particularly in critical areas such as migraine relief and neurodegenerative conditio…
SectorHealthcare
ExchangeNYSE
IndustryBiotechnology
CountryUnited States
Employees274
TickerBHVN
Statistics
Market Cap$2.02B
Revenue (TTM)—
Net Income-$738.8M
Net Margin—
EPS$-6.86
P/E-1.65
P/S—
P/B13.22
EV/EBITDA-2.64
ROE-333.0%
Dividend Yield—
Price$13.44
Data: Twelve Data · Revenue = mcap / P/S